QuatRx raises $44M in fifth venture finance round
QuatRx garnered $44 million in a new round of venture capital. The money is earmarked for the completion of a Phase III and Phase II study of its two endocrine programs. There's also an early-stage trial of a lipid-lowering compound. Venrock led the round. QuatRx has now raised $116 million in venture capital since 2000. The Ann Arbor, MI-based company had filed for an IPO last year but pulled it citing unfavorable market conditions.
- here's the report on QuatRx from Private Equity Hub
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
